Eli Lilly and Company (LLY)vsRockwell Medical Inc (RMTI)
LLY
Eli Lilly and Company
$1,210.32
-0.87%
HEALTHCARE · Cap: $1.02T
RMTI
Rockwell Medical Inc
$6.88
-1.57%
HEALTHCARE · Cap: $24.18M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 106651% more annual revenue ($72.25B vs $67.68M). LLY leads profitability with a 35.0% profit margin vs -8.0%. LLY appears more attractively valued with a PEG of 1.58. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
RMTI
Avoid33
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 34.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : RMTI
RMTI has a balanced fundamental profile.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.
Bear Case : RMTI
The primary concerns for RMTI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while RMTI is a turnaround play — different risk/reward profiles.
RMTI carries more volatility with a beta of 1.61 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 33/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Rockwell Medical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Rockwell Medical, Inc. is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with iron deficiency treatment and hemodialysis products and therapies in the United States and internationally. The company is headquartered in Wixom, Michigan.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?